Raymond schinazi net worth
WebMay 6, 2024 · The current estimated net worth of Cocrystal Pharma, Inc's Raymond F Schinazi is estimated to be about $22.45M . Raymond F Schinazi owns about 7,674,960 … Raymond F. Schinazi is an American organic medicinal chemist with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, in…
Raymond schinazi net worth
Did you know?
WebApr 6, 2024 · The current estimated net worth of Cocrystal Pharma, Inc's Phillip Frost M.D., ... The most active traders at the company are Raymond F Schinazi, Phillip Frost M.D., Individually ... WebIn this section, we analyze the profitability of every unplanned, open-market insider purchase made by Raymond F Schinazi in COCP / Cocrystal Pharma Inc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are ...
WebRaymond F Schinazi Net Worth 2024 and insider trades. Provides CEO, CFO, Director and Chief Executives trade reports, independent equity research, ... S&P 500 Aggregate Buffett … WebMay 8, 2015 · In 2005, an anti-HIV drug he helped develop, FTC, netted $540 million for Emory—which gave $71 million to Schinazi. Emory and Schinazi have made millions more in royalty fees for a sister drug, 3TC, which treats both HIV and hepatitis B. And Schinazi, who also runs a lab at Atlanta's VA Medical Center, had a hand in two other drugs on the market.
WebRaymond F Schinazi Currently, there are two safe and effective therapeutic strategies for chronic hepatitis B treatment, namely, nucleoside analogs and interferon alpha (pegylated … WebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least Precision BioSciences stock worth over $8,979,703 and over the last 8 years Raymond sold DTIL stock worth over $1,696,250
WebMar 26, 2024 · Raymond Schinazi was born in Egypt but left with his family in the 1960s. ... Egypt's new 2024/24 budget to prioritise spending on social safety net programmes.
WebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least Precision BioSciences stock worth over $8,749,454 and over the last 8 years Raymond sold DTIL … curled forkWebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least Precision BioSciences stock worth over $11,665,939 and over the last 8 years Raymond sold DTIL … curled flm on a flatbed scannerWebOct 1, 2024 · Raymond Schinazi: Emory University: 1997: US$154 642: US$241 942: 5R01AI041980-02: 1998: US$205 182: US$316 090: ... Schinazi and colleagues, including ... and Exchange Commission; 2011. Offer to Purchase All Outstanding Shares of Common Stock of Pharmasset, Inc. at US$137 Net Per Share in Cash by Royal Merger Sub Inc. and … curled feetWebAug 20, 2015 · Raymond Schinazi, drug-development pioneer, earns VA's highest honor for biomedical research. August 20, 2015. Dr. Raymond Schinazi, a researcher with the Atlanta VA and Emory University, received VA's 2015 Middleton Award for his development of drugs to treat HIV, hepatitis B, and hepatitis C infections. curled fingers on mousecurled fossilWebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least $8.68 Million dollars as of 4 May 2024. Raymond Schinazi owns over 575,000 units of Precision BioSciences stock worth over $6,984,214 and over the last 8 years Raymond sold DTIL … curled fingers symptomWebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least Precision BioSciences stock worth over $9,440,201 and over the last 8 years Raymond sold DTIL stock worth over $1,696,250 curled font